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Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), continue to be a major cause
of morbidity and mortality in critically ill patients. The present therapeutic strategies for ALI/ARDS including supportive care,
pharmacological treatments, and ventilator support are still controversial. More scientists are focusing on therapies involving
stem cells, which have self-renewing capabilities and diﬀerentiate into multiple cell lineages, and, genomics therapy which has the
potential to upregulate expression of anti-inﬂammatory mediators. Recently, the combination of cell and gene therapy which has
been demonstrated to provide additive beneﬁt has opened up a new chapter in therapeutic strategy and provides a basis for the
development of an innovative approach for the prevention and treatment of ALI/ARDS.
1.Introduction
Acute lung injury (ALI) and its more severe form, the acute
respiratory distress syndrome (ARDS), are syndromes con-
sisting of acute respiratory failure with bilateral pulmonary
inﬁltrates due to intra- or extrapulmonary risk factors [1].
Despite advances in therapeutic principles, the incidence
and outcome of ALI/ARDS are widely considered to have
remained high. In a recent publication [2], the incidence of
ALI and ARDS for patients 15 years of age or older in the
United States, substantially underestimated in the past [3],
was reported to be 78.9 and 58.7 per 100,000 persons per
year, with a mortality rate of 38.5% and 41.1%, respectively.
The incidence of ALI increased with age from 16 per 100,000
person-years for those 15 through 19 years of age to 306
per 100,000 person-years for those 75 through 84 years of
age. Mortality increased with age from 24% for those 15
through 19 years of age to 60% for those 85 years of age
or older. A prospective, multicenter study [4]p e r f o r m e d
in ICUs in Shanghai found a 2% incidence of ARDS for
patients 15 years of age or older with a nearly 70% mortality
rate. As reported data varied widely, a meta-analysis by
Zambon and Vincent [5] published in 2008 concluded that
the overall pooled mortality rate was 43% and there had
indeed been a reduction in mortality rates, approximately
1.1%/year for patients with ALI/ARDS over the last decade.
Although some anticipated trials supported a number of
therapies (e.g., nitric oxide therapy [6], prone positioning
[7], and extracorporeal membrane oxygenation (ECMO)
[8,9])responsibleforimprovementsinALI/ARDSmortality,
Moran et al. [10] argued that a null eﬀect of ECMO was not
excluded and there appeared only weak evidence of eﬃcacy.
AccordingtotheAmerican-EuropeanConsensusConfer-
ence (AECC) on ARDS [1, 11], the diagnostic criteria are
the presence of acute hypoxemia with a ratio of the partial
pressure of arterial oxygen to the fraction of inspired oxygen
(PaO2 :FiO 2)of300mmHgorless(forALI)orof200mmHg
or less (for ARDS); bilateral inﬁltrates on chest radiograph
and no clinical evidence of left atrial hypertension or a
pulmonary artery wedge pressure of 18mmHg or less. It has2 Mediators of Inﬂammation
been extensively adopted that the lung injury score or the
Acute Physiology and Chronic Health Evaluation (Apache
III) or Simpliﬁed Acute Physiology Score (SAPS II) scoring
systems can be applied to assess the severity of ALI/ARDS
and the associated clinical features [12, 13]. Nevertheless,
the GOCA stratiﬁcation system (gas exchange, organ failure,
cause, and associated diseases) was recommended by AECC
[11] to facilitate incorporation of additional clinical infor-
mation and prediction of outcome.
Frequently, ALI/ARDS has been noticed to have systemic
manifestations because its triggering conditions are systemic
and impairment of the lung leads to sepsis or inﬂammatory
response syndrome [14, 15]. Most studies [4, 5, 16, 17]
have shown that patients with refractory ALI/ARDS died
of multiple organ dysfunction syndromes (MODSs), rather
thanisolatedrespiratoryfailure.Tillnowthereisnouniversal
theory concerning the pathogenesis of ALI/ARDS, but it can
be understood to be any cellular or molecular mechanism
associated with inﬂammatory pathways implicated in lung
injury. Some reviews [18, 19] supported the ﬁndings that
the alveolar epithelium along with lung leukocytes and
coagulation pathway play a key role in the formation and
clearance of ALI/ARDS and outcomes can be improved by
increasing the rate of liquid clearance through β-adrenergic
stimulation. On the other hand, several compounds which
are either synthesized by or act on endothelial cells have been
used for lung injury treatment in experimental studies or in
human trials.
The present therapeutic approaches for ALI/ARDS con-
sist of supportive care, pharmacological treatments, and
ventilatory support including high-frequency ventilation
(HFV), inverse ratio ventilation (IRV), airway pressure
release ventilation (APRV), positioning of the patients,
exogenous surfactant administration, liquid mechanical
ventilation and extracorporeal membrane oxygenation
(ECMO), and carbon dioxide removal (ECCO2R). How-
ever, the beneﬁt of innovative ventilatory strategies is still
controversial [20]. Combined respiratory care and inhaled
nitric oxide have not been shown rigorously to improve
overall mortality [4]. A research [21] conducted by Slutsky
and Tremblay revealed a vicious cycle that mechanical
ventilation, although being an indispensable tool for provid-
ing adequate gas exchange and resting respiratory muscles
in certain patients with ARDS, may contribute to the
initiation and/or propagation of a systemic inﬂammatory
response leading to MODS. At the heart of the dilemma,
the question remains “what is the most eﬀective way to
recover multiple organ failure?” In an attempt to escape
this vicious cycle, innovative approaches, cell and/or gene
therapy, are now being contemplated. We searched several
electronic databases including Medline through PubMed
(1990 to 2011), EMBASE through OVID (1990 to 2011)
and Web of Science (1990 to 2011) and also reviewed the
Cochrane Library to ﬁnd relevant articles and searched the
reference lists from primary and review articles to ﬁnd
articles concerning cell and/or gene therapy for ALI/ARDS.
This paper aimed to provide some background material
and highlight the importance and promise of these new
therapeutic strategies.
2. Cell Therapies for ALI/ARDS
Recently,therapyinvolvingstemcells,whichhaveclonogenic
and self-renewing capabilities and diﬀerentiate into multiple
cell lineages [22, 23] has become eye catching. The stem cells
evaluated for this purpose include mesenchymal stem cells
(MSCs) and embryonic stem (ES) cells.
Studies have demonstrated that treatment with MSCs
provides a signiﬁcant survival advantage both by sys-
temic administration in experimental models of bleomycin-
induced lung injury [24, 25] and through intrapulmonary
delivery in mice with endotoxin-mediated ALI [26, 27].
One explanation of persistent lung injury and ﬁbrosis
attenuation is that MSCs not only migrate to the termination
of acute inﬂammation in the lungs and diﬀerentiate into
organ-speciﬁc cells [28], but increase the production of
growth factors that may mobilize endogenous stem cells.
Both increased mobilization of endogenous progenitor cells
and alterations in the local cytokine milieu in favor of
repair may contribute to the protective eﬀects of stem cell
transplantation as outlined by Rojas et al. [25]. Another
theory of protection holds that MSCs shift the balance from
a proinﬂammatory to an anti-inﬂammatory response to
endotoxin or bleomycin that includes enhanced production
of IL-10 [26] and blocking TNF-α and IL-1 [29]. Despite
this, there is strong evidence that progenitor cells do have
the capacity to engraft and contribute to the mesenchymal
compartment of the lung, the consequences of which may be
eitherbeneﬁcialorharmful[30],dependinguponthelineage
of engrafting cells [31].
E m b r y o n i cs t e mc e l l sh a v eb e e nr e g a r d e da sa n o t h e r
new perspective for cell therapy for ALI/ARDS. The capacity
o fE Sc e l l st og e n e r a t et y p eI Ip n e u m o c y t e sa n dc e l l so f
diﬀerentiated airway epithelial tissue, including basal cells,
ciliated cells, intermediate cells, or Clara cells have been
uncovered [32, 33]. Nevertheless, a major concern with the
use of embryonic stem cells for therapeutic purposes is their
potential to form teratomas in vivo; such tumorigenicity is
thus far unknown for pluripotent adult progenitor cells [34].
In contrast to previous reports, Kotton et al. [35]
provided the evidence of failure to detect reconstitution of
lung alveolar epithelial cells by unfractionated bone marrow
or puriﬁed hematopoietic stem cells after transplantation
when autoﬂuorescence and dead cells are excluded from
analysis. This ﬁnding has been supported by Loi et al.
[36] who demonstrated that bone marrow derived cells
home to airway epithelium with a low frequency by current
techniques. Further investigation, therefore, on the molec-
ular mechanisms that govern marrow cell recruitment and
phenotypic conversion is needed in order for this approach
to be clinically feasible.
3. Gene Therapies for ALI/ARDS
More and more scientists are focusing on functional
genomics approaches which have great potential to address
questions related to changes in phenotypes of key cells
in ALI/ARDS [37–39]. For example, injury mechanisms
mediated by the release of granular enzymes or oxygenMediators of Inﬂammation 3
radicals by neutrophils, aggregation of neutrophils, mono-
cytes and platelets, and activation of the clotting cascade
use constitutive biochemical pathways and do not require
induction of new transcripts or expression of new proteins.
Furthermore, constitutively expressed but repressed messen-
ger RNAs can be translated to proteins in response to cellular
signals that are relevant to ALI/ARDS and its systemic man-
ifestations. Thus, genomic approaches using microarrays
and other methods have rapidly become major tools in
biologic investigation and are increasingly being applied in
ALI/ARDS. Among all the genomics strategies, one of the
most eﬀe c t i v eo n ei st ou p r e g u l a t eg e n ee x p r e s s i o nf o ra n t i -
inﬂammatory mediators such as Endothelial Nitric Oxide
Synthase (eNOS), inhibitory kappa B (I-κB), Keratinocyte
growth factor (KGF), and angiopoietin-1.
Among the inﬂammatory reactions that lead to injury,
nitric oxide (NO), synthesized by isoforms of NO synthase
(NOS) such as endothelial NOS (eNOS), constitutive neu-
ronal NOS (nNOS) and inducible NOS (iNOS), is an impor-
tant factor that regulates microvascular permeability during
the pathogenesis of ALI. It has been demonstrated [40,
41] that under chemical or inﬂammatory stress, increased
NO production occurs primarily via the iNOS isoform. In
addition, overabundance of NO causes autoinhibition of its
own synthesis, with eNOS being more sensitive to feedback
than the inducible isoform. Since the 1980s, extensive
researches in the ﬁeld of NO and ALI/ARDS have produced
mixed results, adding to the uncertainty of manipulating the
delicate balance between NO’s therapeutic beneﬁts and its
toxic eﬀects. Systematic reviews [42–44] failed to identify
statistically signiﬁcant beneﬁcial eﬀects of inhaled NO on
clinical outcomes. Despite signs of transient improvement
in oxygenation, inhaled NO may be hazardous since it
may cause kidney function impairment. Therefore, recent
studies have investigated the nonselective NOS and iNOS
selective inhibitors. In contrast with the data supporting the
inhibition of iNOS leading to the beneﬁcial inﬂuence in
animal models, nonselective inhibition of NOS has multiple
adverse eﬀects [41]. Thus, the potential roles of eNOS in
ALI/ARDS need to be clariﬁed. Although Yamashita et al.
[45] previously reported that chronic eNOS overexpression
results in resistance to lipopolysaccharide-(LPS-) induced
endotoxin shock using eNOS transgenic mice overexpressing
the bovine eNOS gene in endothelial cells, they modiﬁed
the study of design by establishing a mechanical ventilation
model using eNOS transgenic mice without stimulation of
iNOS expression and activity and have still strengthened the
notion that NO derived from chronic eNOS overexpression
inhibited neutrophil-associated lung edema and inﬂamma-
tion by reducing cytokine production in lung injury [46].
Because of the distinction in response between the rodent
and human model, the clinical eﬀect and approach of eNOS
delivery should be evaluated by further studies.
ThetranscriptionfactornuclearfactorkappaB(NFκB)is
a central regulator of inﬂammatory and immune responses.
It remains in an inactive form in the cytoplasm because of
its association with inhibitory proteins (IκBs) and migrates
to nucleus when NFκB is activated by stimuli leading to
phosphorylation and subsequent degradation of the IκB
proteins. Recently, it has been shown that overexpression of
IκBα or NFκB decoy transfection decrease NFκB activity and
IL-8 secretion not only in endothelial and stromal cells and
monocytes [47, 48], but in epithelial cells also [49]. Anti-
inﬂammatorygenetherapybasedonnucleotidegenetransfer
mayoﬀerpromiseforALI/ARDSbutlargeclinicalstudiesare
yet lacking.
Keratinocytegrowthfactor(KGF)isanepithelial-speciﬁc
growth factor secreted by ﬁbroblasts and vascular smooth
muscle cells. It has recently been discovered to be the
principal mitogen for alveolar type II cells [50]. Baba et
al. have demonstrated that transient overexpression of KGF
in the lungs attenuate pathophysiological impairments in
hyperoxia-induced acute lung injury in mice due to the
proliferation of epithelial cuboidal cells and the increase of
Ki67—and surfactant protein C (Sp-C)-positive cells [51].
This suggests that the protective properties of KGF are the
product of multifactorial eﬀects. In Stern et al.’s recent
study [52] ,K G Fw a sn o td e t e c t e di nt h eB A Lﬂ u i do f
the 15 survivors except in one patient, whereas KGF was
greater than the threshold in 13 of the 17 nonsurvivors
patients. This is not contradictory with the results of
previous studies [51, 53] in animals that demonstrated that
intratracheal or intravenous administration of KGF protects
against lung injury. However, in most experimental studies,
KGF was given in large amounts (5mg/kg), 48 or 72hrs
before the injury. It is, therefore, possible that the time of
administration is a key factor. Elevation of KGF may occur
too late in vivo, at a time where epithelial damage is already
maximal.Actually,Sternetal.[54]havealreadyreportedthat
in ALI/ARDS human subjects, KGF is found at biologically
activelevelsinthealveoli,actinginconcertwithparathyroid-
hormone-related protein to regulate the apoptosis and cell
proliferation balance in the alveolar epithelium. Thus, KGF
gene transduction is supposed to be a potentially useful
method to overcome the critical phase of ALI/ARDS despite
the disadvantages of epithelial cell or type II cell hyperplasia
related to the overexpression of KGF in the lungs [55].
As a ligand for the endothelial-speciﬁc receptor tyrosine
kinase with immunoglobulin and epidermal growth factor
homology domain 2 (Tie2), angiopoietin-1 (Ang1) plays
a crucial role in embryonic vasculature development [56,
57]. It has been reported in experimental studies that
Ang1 can act as an anti-inﬂammatory factor by reducing
pulmonary inﬂammation, plasma extravasation, and the
increase of cytokines and adhesion molecules. Some data
haverevealedthatAng1amelioratesreactive-oxygen-species-
(ROS-) induced ALI through attenuating vascular leakage
and modulating the expression of inﬂammatory mediators
[6, 58]. The clinical trial conducted by Van Der Heijden
et al. [59] showed that Ang1 levels were lower in patients
with ALI/ARDS than in controls. These ﬁndings provide
a rationale that Ang1 can be a recommendable anti-
inﬂammatory target for ALI/ARDS. However, the possible
side eﬀects of Ang1 treatment have been noticed lately,
including the development of pulmonary hypertension,
lymphatic sprouting, and proinﬂammatory and proﬁbrotic
eﬀects in acute renal injury [60–62]. Therefore, future
researches need to be focused on the two most studied Tie24 Mediators of Inﬂammation
ligands Ang1 and Ang2—interferes with Ang-1 activation by
preventing Ang-1 from binding to the receptor—to optimize
therapeutic strategy for the treatment of ALI/ARDS.
4. CellBased GeneTherapies for ALI/ARDS
Gene therapy is widely accepted to be a promising treatment
option for both genetically determined and idiopathic dis-
eases. However, the use of viral vectors has been problematic,
ranging from host immune responses to tumorigenesis. To
overcomethelimitationoftransientgeneexpressionthrough
c l a s s i ca d e n o v i r a lv e c t o r s ,G r o v ee ta l .[ 63] used an approach
ofretrovirallytransducedmultipotentbone-marrow-derived
stem cells (BMSCs) to deliver gene therapy to the lung
epithelium and up to 20% of lung epithelial cells can be
derived from BMSCs.
Therefore, a novel therapeutic approach, cell-based gene
therapy with the combination of cell and gene therapies
has proven to be successful in experimental pulmonary
vascular disease from ALI/ARDS [64–66]o rp u l m o n a r y
hypertension [67, 68]. Histologically, human ALI/ARDS
can be subdivided into the exudative phase and the sub-
sequent ﬁbroproliferative phase [69]. The exudative phase
is characterized by a diﬀuse neutrophilic alveolar inﬁltrate
with hemorrhage, the accumulation of macrophages and
protein-rich pulmonary edema. Endothelial injury and
subsequent loss of integrity of the endothelial barrier is
a prerequisite for development of interstitial edema and
increase in permeability. These insights into the mechanisms
of injury and inﬂammation during ALI/ARDS have brought
attention to therapeutic strategies targeting the pulmonary
endothelium. In the work by McCarter et al. [64], they used
skin ﬁbroblasts cell-based gene therapy in a rat model of
ALI to achieve targeted overexpression of Ang-1 in the lung
microvasculature while circumventing the problems of in
vivo transfection and avoiding the confounding eﬀects of
viral proteins. Overexpression of angiopoietin-1, a ligand of
the endothelial-selective tyrosine-kinase receptor, along with
protective enzymes of eNOS and heme oxygenase-1 (HO-1),
sustained less lung injury. This therapeutic strategy could be
advantageous over intravenous administration of recombi-
nant Ang-1 protein, as it allows for more targeted expression
of the transgene and overcomes issues of short protein
half-life after injection. In their further investigation [65],
there was an additional eﬀect of Ang1 overexpressing MSCs
compared with MSCs alone, not only on the extravasation of
plasmaproteinsandinﬂammatorycells,butalsoonthelevels
of various inﬂammatory cytokines and chemokines in the
BAL ﬂuid. This synergistic eﬀect of MSCs-based Ang1 gene
transfer may be attributed to its ability to reduce endothelial
cellactivationandthusblocktheampliﬁcationoflunginjury
that is dependent on the recruitment of leukocytes from the
pulmonary circulation into the injured lung. Nevertheless,
it is clear that the beneﬁt seen in response to cell-based
therapy did not require a high level of long-term persistence
of transplanted MSCs. This observation is consistent with a
number of reports [70], which point to an important role for
paracrine actions of transplanted cells on neovascularization
and tissue healing. Interestingly, this beneﬁt has also been
supported in our research[66]. The LPS-inducedlung injury
was markedly alleviated in the group treated with MSCs
carrying Ang1 compared with groups treated with MSCs or
Ang1 alone. The expression of Ang1 protein in the recipient
lungs was increased after MSCs-Ang1 administration. In
addition, cells of MSC origin could be detected in the
recipient lungs for 2 weeks after injection with MSCs. All the
ﬁndings suggest that MSCs and Ang1 have a synergistic role
in the treatment of LPS-induced lung injury, as MSC-based
Ang1 administration may concentrate in the vessel-enriched
lung tissue. However, the precise mechanism by which
genetically engineered MSCs confer a therapeutic beneﬁt in
the model of ALI/ARDS remains to be determined. Besides,
the endothelial progenitor cells (EPCs), a tissue engineer
to reconstruct pulmonary vasculature, have been used to
protect the tissue from ALI manipulated with gene transfer
(such as nitric oxide, prostacyclin, and adrenomedullin)
[15] since dysfunction of pulmonary vascular endothelium
may play a role in the pathogenesis of pulmonary hyper-
tension associated with ALI/ARDS. Zhao et al. [68]h a v e
reported that endothelial progenitor cells (EPCs) engineered
to overexpress eNOS were signiﬁcantly more eﬀective than
EPCs alone in a monocrotaline model of vascular injury,
producing near complete reversal of established pulmonary
hypertension. A number of clinical trials are required to
assess the safety and eﬃcacy of cell-based gene therapy in
several diﬀerent pathologies.
Despite the limitations of low percentage of the retained
cells in lung and uncertainty of host immune response,
the synergistic action of combined cell and gene therapy
for ALI/ARDS not only allows direct targeting of the lung
for clinical intervention, but also provides a site-speciﬁc
source to release therapeutic proteins and/or other cellular
products by the retained cells. Cell-based gene therapy for
ALI/ARDS has opened up a new chapter in therapeutic
strategy and provides a basis for the development of an
innovative approach for the prevention and treatment of
ALI/ARDS.
5. Conclusion
The acute lung injury (ALI) and its more severe form,
acute respiratory distress syndrome (ARDS), continue to be
a major cause of morbidity and mortality in critically ill
patients. Interventional approaches such as cell therapy and
genetherapyforALI/ARDShaveemergedwhileclassicthera-
peutic strategies are still widely adopted. The combination of
cell and gene therapy that has been demonstrated to provide
additive beneﬁts holds the promise of major contribution to
the repair, replacement, and regeneration of damaged tissues
and organs. Cell-based gene therapy, therefore, is supposed
to be an expected approach to ALI/ARDS.
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